Targeting PIK3CA in Her2 -Positive Breast Cancer: What Are the Opportunities and the Challenges?

SNORD60 promotes the tumorigenesis and progression of endometrial cancer through binding PIK3CA and regulating PI3K/AKT/mTOR signaling pathway

“…Kaplan‐Meier Plotter survival analysis indicated that the expression of PIK3CA in endometrial carcinoma was positively correlated with the survival rate of patients, the 5‐year survival rate or Overall survival (months) rate of patients with high PIK3CA expression was significantly lower than that of patients with low PIK3CA expression (Figure 4C). The p110α protein encoded by PIK3CA is involved in the formation of the catalytic subunit of phosphatidylinositol 3‐kinase (PI3K), which has been found to be carcinogenic 15–17 . Here, the results of RIP and a biotinylated‐SNORD60‐based RNA pulldown assay indicated that 2’‐O‐methyltransferase FBL can bind to PIK3CA mRNA (Figure 4D) and SNORD60 directly (Figure 4E).…”

“…The p110α protein encoded by PIK3CA is involved in the formation of the catalytic subunit of phosphatidylinositol 3-kinase (PI3K), which has been found to be carcinogenic. [15][16][17] Here, the results of RIP and a biotinylated-SNORD60based RNA pulldown assay indicated that 2'-O-methyltransferase FBL can bind to PIK3CA mRNA (Figure 4D) and SNORD60 directly (Figure 4E). However, SNORD60 can not bind to Ago2 (Figure 4F), which is essential for the sno-miRNA function of snoRNAs, indicated that SNORD60 may not function in a miRNA-like role.…”

A Potential PIK3CA Inhibitor to Develop an Anticancer Drug

“…These results are important to have an overview of the potential of C5 compound for its development as an anticancer drug; however, our study needs more assays to analysis detailed mechanistic of C5 compound with the PI3 K/Akt/mTOR signaling pathway, [19] like proteomic and western blot analysis. Therefore, C5 compound shows favorable results to develop a new anticancer drug, in addition, PIK3CA has demonstrated as a therapeutic target in different in vitro and in vivo cancer cell assays [3,26–29] . Therefore, PIK3CA could be another alternative to affect the viability cancer cell, and this study could contribute efforts to develop better anticancer drugs.…”

“…[17,[20][21][22] It has been reported that PIK3CA plays a critical role in a variety of tumors and is strongly related to tumor proliferation and migration. [23][24][25][26] In this study was evaluated a compound selected by molecular docking against PIK3CA, that could generate an anticancer effect to develop a new drug. The PI3K has characteristics that might help to develop a specific PIK3CA inhibitor, because there are studies that propose amino acids in the catalytic subunit p110α that frequently mutated in cancer (mainly breast, endometrial, colon, brain, and gastric cancers), [19,20] to generate an inhibition or alter its functions in the cancer cell, and there are few inhibitors reported on this specific target [3,[27][28][29] with promising results that demonstrated PIK3CA might be a good therapeutic target.…”

“…Therefore, PIK3CA has been proposed as a therapeutic target since it has functions related to the development of various types of cancer, [23–26] there are advances in the development of PIK3CA inhibitors, [3,27–29] combinations of these with conventional drugs have been developed, [28] and tests on humans too [23,25,28] . Thus, PIK3CA is being used as a therapeutic target against cancer.…”